The site will be unavailable from 11:00 PM GMT on Tuesday, 21 July 2026, until 4:00 AM GMT on Wednesday, 22 July 2026, due to scheduled maintenance.

Renal cell carcinoma

15th Nov 2024

Quality of life in CheckMate 9ER: cabozantinib and nivolumab for advanced renal cell carcinoma

Axitinib is a medication that stops cancer cell growth by depriving the cancer cell of the nutrients and oxygen that it needs. Axitinib is used to treat advanced renal cell carcinoma (RCC), which is a type of kidney cancer that has spread within or beyond the kidney. Axitinib has been approved for the treatment of RCC as either a first treatment option or a second treatment option. It is used as a first treatment option for RCC when combined with a medication that reactivates the immune system (immunotherapy), either avelumab or pembrolizumab. If the advanced RCC starts growing again it can be used as a second treatment option where it is taken by itself. It is essential to conduct studies to assess how well the drug works and whether it has any side effects in order to understand whether it is safe to give to people.

1st Aug 2023

Renal cell carcinoma

Quality of life in CheckMate 9ER: cabozantinib and nivolumab for advanced renal cell carcinoma

Plain Language Summary: looking at how long side effects last after stopping axitinib treatment in people with advanced renal cell carcinoma